Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2014
- Source ID
- 10.1016/j.bbmt.2014.05.021
Entities
People
- Bipin N Savani
- Carolyn Keever-taylor
- David Szwajcer
- David Valcarcel
- Hillard M Lazarus
- Jennifer Le Rademacher
- Johan Törlén
- Junfang Chen
- Mary Eapen
- Mary J. Laughlin
- Michael Lill
- Miguel-Angel Perales
- Minoo Batiwalla
- Olle Ringden
- Partow Kebriaei
- Tamila Kindwall-keller
- Tom Erkers
- Tracey O’brien
- Vanderson Rocha
- Vincent Ho
Organizations
- ARIAD Pharmaceuticals
- Actinium Pharmaceuticals (United States)
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- Health Research
- Incyte
- Kiadis Pharma (Netherlands)
- Medical College of Wisconsin
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- St. Baldrick's Foundation
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)
- Terumo BCT (United States)
- Texas Instruments